{"DataElement":{"publicId":"7810096","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Disposal Specify Text","preferredDefinition":"The free-text field to describe the filgrastim or bioequivalence agent that was disposed.","longName":"7810083v1.0:2799057v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7810083","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent Disposal","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1)._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The act or means of getting rid of something.","longName":"7810079v1.0:5632759v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7810079","version":"1","preferredName":"Filgrastim Or Bioequivalence Agent","preferredDefinition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C1474:C37998:C71763:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0117CDB-A5DF-5E9A-E053-4EBD850ABA81","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5632759","version":"1","preferredName":"Disposal","preferredDefinition":"The act or means of getting rid of something.","longName":"C48166","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disposal","conceptCode":"C48166","definition":"The act or means of getting rid of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46D7747E-B3D7-47A3-E053-F662850A8F55","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-24","modifiedBy":"ONEDATA","dateModified":"2017-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0109618-A628-455B-E053-4EBD850A88D4","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"MALUMK","dateModified":"2021-12-20","changeDescription":"Released. 12/20/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2799057","version":"1","preferredName":"Specify Text","preferredDefinition":"Be specific about something; define clearly._Text; the words of something written.","longName":"SPC_TXT","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2799056","version":"1","preferredName":"Specify Text","preferredDefinition":"Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D89B-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"ONEDATA","dateModified":"2008-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D8AC-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"MALUMK","dateModified":"2021-01-19","changeDescription":"03/17/10-Added CSI for F2000-CJL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other brand of filgrastim or similar:","type":"Alternate Question Text","description":"Other brand of filgrastim or similar:","url":null,"context":"NHLBI"},{"name":"Other brand of filgrastim or similar:","type":"Application Standard Question Text","description":"Other brand of filgrastim or similar:","url":null,"context":"NHLBI"},{"name":"Specify the filgrastim or bio","type":"Preferred Question Text","description":"Specify the filgrastim or bioequivalence agent that was disposed:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00F3EE7-69A5-4B34-E053-4EBD850A08EC","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-11-05","modifiedBy":"MALUMK","dateModified":"2021-12-21","changeDescription":"Released. 12/20/2021 KMM. Updated ASQT/ AQT. 12/21/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}